The Phase I/II trial conducted by Oslo University Hospital investigates the safety and immunogenicity of a novel mRNA-based dendritic cell vaccine for advanced malignant melanoma. Given the increasing incidence of melanoma and the limited efficacy of current therapies, this approach could address a significant unmet medical need. The competitive landscape includes established immunotherapies such as checkpoint inhibitors and emerging mRNA therapies. Successful outcomes could position this therapy favorably in the melanoma treatment market, which is projected to grow significantly. Diligence should focus on the trial's safety profile, potential for combination therapies, and the regulatory pathway for mRNA-based vaccines.